相关实验视频
Updated: Mar 7, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
19.1K
赫萨拉作为一种潜在的治疗策略,用于治疗多病症
Ángel Juan García-Yagüe1, Daniel Carnicero-Senabre1, Ángel Núñez2
1Department of Biochemistry, School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain; Instituto de Investigaciones Biomédicas "Sols-Morreale" (CSIC-UAM), Madrid, Spain; Instituto de Investigación Sanitaria La Paz (IdiPaz), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Redox biology
|March 5, 2026
概括
赫萨拉 (HXN) 是来自Wasabia japonica的化合物,在阿尔茨海默病模型中有效降低了病态TAU酸化. 这种神经保护作用是由PP2A酸酶激活的介导,这表明HXN是病的潜在治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 涉及TAU蛋白的高酸化,导致神经退行.
- 赫萨拉 (HXN) 是一种 Wasabia japonica 化合物,已知具有神经保护作用,但其在 TAU 病理学中的作用尚未被探索.
研究的目的:
- 为了研究HXN对病理性TAU酸化的影响.
- 阐明HXN在体外和体内作用的基础分子机制.
主要方法:
- 来自APP/TAU转基因小鼠 (NRF2野生类型和淘汰赛) 的初级神经元被使用.
- 使用了遗传学和药理学方法,包括酸酶试验.
- 在APP/TAU小鼠中进行了慢性口服HXN.
主要成果:
- 在独立于NRF2.2,HXN显著降低了病理性TAU表位 (AT8,PHF1) .
- HXN通过PP2A激活促进TAU脱化,而不是通过抑制GSK-3β或改变PI3K/AKT/MAPK通路.
- 在体内,HXN降低了大脑和血液中的酸-TAU水平,减弱了神经炎症,保留了神经元,并改善了认知和运动功能.
结论:
- 通过PP2A激活,HXN是病理性TAU酸化的强大的调节器.
- 在阿尔茨海默病和其他TAU驱动的神经退行性疾病中,HXN显示出改变疾病的潜力.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K